Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of a Risk Score

Dong Wook Kim(Ulsan College), Song Cheol Kim(Ulsan College), Kyu‐pyo Kim(Ulsan College), Jae Ho Byun(University of Ulsan), Seung Soo Lee(Asan Medical Center), Hyoung Jung Kim(University of Ulsan), Changhoon Yoo(Ulsan College), Seon‐Ok Kim(Ulsan College), Jin Hee Kim(University of Ulsan), Ki Byung Song(Ulsan College)
Radiology
July 14, 2020
10.1148/radiol.2020200281
Cited by 52

Related Papers

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers
|Proceedings of the National Academy of Sciences|2017|577
A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts
|Gastroenterology|2015|472
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis
|JNCI Journal of the National Cancer Institute|2019|299
Autoimmune Chronic Pancreatitis
|The American Journal of Gastroenterology|2004|288